Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TBI 1201

Drug Profile

TBI 1201

Alternative Names: MAGE-A4 antigen-specific RetroNectin® TCR gene therapy - Takara Bio; MAGE-A4 antigen-specific TCR modified lymphocytes - Takara Bio; MAGE-A4 TCR-transduced T-cell therapy - Takara Bio; MAGE-A4-targeted T-cell therapy - Takara Bio; TBI-1201

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takara Bio
  • Developer Mie University; Takara Bio
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Oesophageal cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Recurrent, Refractory metastatic disease, Second-line therapy or greater) in Japan (IV)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Oesophageal-cancer(Combination therapy, Second-line therapy or greater) in Japan (IV)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Oesophageal-cancer(Monotherapy, Second-line therapy or greater) in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top